On 19 April 2011, the US Food and Drug Administration (FDA) approved rituximab in combination with glucocorticosteroids for the treatment of two forms of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV): granulomatosis with polyangiitis (Wegener’s) and microscopic polyangiitis. Rituximab is the first FDA approved drug for ANCA-associated vasculitis.
Rest of this article is here.
What I have to say: From talking to patients who are taking this treatment, they have less side-effects than using cyclophosphamide. This is a great break-through for Vasculitis patients.